Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Inmunova logo — Somos una compañía biotecnológica argentina dedicada a la in...

Inmunova

Somos una compañía biotecnológica argentina dedicada a la investigación y desarrollo de medicamentos innovadores.

Founded 2009 Argentina San Martin, Argentina 35 employees Biopharma, Biotechnology

General Information

Company Name Inmunova
Founded Year 2009
Location Argentina San Martin, Argentina
Employees 35
Industries Biopharma, Biotechnology
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Inmunova. To contact Inmunova, visit inmunova.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Inmunova compare?

A PDF of Inmunova and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Inmunova soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Inmunova

Inmunova is an Argentine biotechnology company, renowned for its commitment to the research and development of innovative medications. Established in 2009, the company builds on the pioneering work of Dr. Fernando Goldbaum’s Laboratory at Fundación Instituto Leloir.

The company’s primary innovation is its proprietary platform, Immuno Multi Carrier (IMC®), which facilitates the engineering of advanced recombinant vaccines and immunomodulators. This cutting-edge technology has already garnered patents in major markets, including the USA, Canada, EU, Japan, China, India, Brazil, Mexico, and Argentina, indicative of its global potential and scalability.

While Inmunova has yet to report its latest investment round, its strategic positioning in the Biopharma and Biotechnology sectors makes it a compelling prospect for investors looking to capitalize on frontier technologies in healthcare innovation.

Business keywords: drug development, innovative medicines, recombinant vaccines, immunomodulators, proprietary technology, Immuno Multi Carrier platform, patented technologies, biotech research, scientific innovation, immunotherapy, pharmaceutical R&D, vaccine design

Services & Products

Research and Development of innovative drugs
Engineering of proteins and antibodies
Clinical trials and regulatory affairs management
Publications and scientific communication

Target Customers

Healthcare professionals Pharmaceutical companies Research institutions Patients with rare and infectious diseases

No funding data available for Inmunova yet.

Inmunova Alternatives & Competitors

View All Alternatives
Inmunova vs
Advaccine
Advaccine China

Advancing Vaccines，Improving Immunotherapeutics

Private Equity
5 employees
Biopharma, Biotechnology
Inmunova vs
OrganoTherapeutics
OrganoTherapeutics Luxembourg

Using Midbrain Organoids for the development of new Therapeutics against Parkinson`s Disease.

9 employees
Biopharma, Biotechnology
Inmunova vs
HilleVax
HilleVax United States

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel va...

Post-IPO Equity
76 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Inmunova

Somos una compañía biotecnológica argentina dedicada a la investigación y desarrollo de medicamentos innovadores.
Inmunova was founded in 2009.
Inmunova is headquartered in San Martin, Argentina.
Inmunova operates in Biopharma and Biotechnology. Its work centres on drug development, innovative medicines, recombinant vaccines and immunomodulators. Its customers include Healthcare professionals, Pharmaceutical companies and Research institutions.
Inmunova has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Inmunova has approximately 35 employees.
Inmunova offers: Research and Development of innovative drugs, Engineering of proteins and antibodies, Clinical trials and regulatory affairs management, Publications and scientific communication.
Top alternatives and competitors to Inmunova include Advaccine, OrganoTherapeutics, HilleVax, Emalex Biosciences, Adendra Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inmunova and Advaccine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inmunova, https://bouncewatch.com/company/inmunova-sa, updated 30 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes